"T-Lymphocytes, Cytotoxic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Descriptor ID |
D013602
|
MeSH Number(s) |
A11.118.637.555.283.875 A11.118.637.555.567.550.500.200 A11.118.637.555.567.569.220.200 A11.118.637.555.567.569.500.200 A15.145.229.637.555.283.875 A15.145.229.637.555.567.550.500.200 A15.145.229.637.555.567.569.220.200 A15.145.229.637.555.567.569.500.200 A15.382.490.555.283.875 A15.382.490.555.567.550.500.200 A15.382.490.555.567.569.220.200 A15.382.490.555.567.569.500.200
|
Concept/Terms |
T-Lymphocytes, Cytotoxic- T-Lymphocytes, Cytotoxic
- Cytotoxic T-Lymphocyte
- T Lymphocytes, Cytotoxic
- T-Lymphocyte, Cytotoxic
- Cell-Mediated Lympholytic Cells
- Cell Mediated Lympholytic Cells
- Cell, Cell-Mediated Lympholytic
- Cell-Mediated Lympholytic Cell
- Cells, Cell-Mediated Lympholytic
- Lympholytic Cell, Cell-Mediated
- Lympholytic Cells, Cell-Mediated
- Cytotoxic T-Lymphocytes
- Cytotoxic T Lymphocytes
TC2 Cells- TC2 Cells
- Cell, TC2
- Cells, TC2
- TC2 Cell
TC1 Cells- TC1 Cells
- Cell, TC1
- Cells, TC1
- TC1 Cell
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes, Cytotoxic".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Cytokine-Induced Killer Cells [A11.118.637.555.283]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.283.875]
- Lymphocytes [A11.118.637.555.567]
- Lymphocyte Subsets [A11.118.637.555.567.550]
- T-Lymphocyte Subsets [A11.118.637.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.550.500.200]
- T-Lymphocytes [A11.118.637.555.567.569]
- CD8-Positive T-Lymphocytes [A11.118.637.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.569.220.200]
- T-Lymphocyte Subsets [A11.118.637.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.569.500.200]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A15.145.229.637]
- Leukocytes, Mononuclear [A15.145.229.637.555]
- Cytokine-Induced Killer Cells [A15.145.229.637.555.283]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.283.875]
- Lymphocytes [A15.145.229.637.555.567]
- Lymphocyte Subsets [A15.145.229.637.555.567.550]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.550.500.200]
- T-Lymphocytes [A15.145.229.637.555.567.569]
- CD8-Positive T-Lymphocytes [A15.145.229.637.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.569.220.200]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.569.500.200]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Cytokine-Induced Killer Cells [A15.382.490.555.283]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.283.875]
- Lymphocytes [A15.382.490.555.567]
- Lymphocyte Subsets [A15.382.490.555.567.550]
- T-Lymphocyte Subsets [A15.382.490.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.550.500.200]
- T-Lymphocytes [A15.382.490.555.567.569]
- CD8-Positive T-Lymphocytes [A15.382.490.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.569.220.200]
- T-Lymphocyte Subsets [A15.382.490.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.569.500.200]
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes, Cytotoxic".
This graph shows the total number of publications written about "T-Lymphocytes, Cytotoxic" by people in this website by year, and whether "T-Lymphocytes, Cytotoxic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 0 | 1 |
1999 | 1 | 0 | 1 |
2000 | 1 | 0 | 1 |
2001 | 2 | 0 | 2 |
2002 | 1 | 1 | 2 |
2003 | 2 | 0 | 2 |
2005 | 1 | 1 | 2 |
2007 | 1 | 0 | 1 |
2008 | 2 | 0 | 2 |
2009 | 2 | 0 | 2 |
2015 | 1 | 0 | 1 |
2016 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "T-Lymphocytes, Cytotoxic" by people in Profiles.
-
Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell. 2022 02 03; 185(3):493-512.e25.
-
Mannose receptor induces T-cell tolerance via inhibition of CD45 and up-regulation of CTLA-4. Proc Natl Acad Sci U S A. 2016 09 20; 113(38):10649-54.
-
Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat Commun. 2015 Sep 25; 6:8306.
-
The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. Int J Cancer. 2009 Nov 15; 125(10):2474-8.
-
Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. J Immunother. 2009 Feb-Mar; 32(2):157-60.
-
Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res. 2008 Oct 15; 14(20):6574-9.
-
Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res. 2008 Mar-Apr; 28(2A):779-84.
-
Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. Blood. 2007 Oct 15; 110(8):2931-9.
-
Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol. 2005 Sep; 141(3):558-62.
-
Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer. 2005 Jun 10; 115(2):333-6.